RECOVERY / PEPTIDE CARD

TB-500

A marketed name for a synthetic thymosin-beta-4-related fragment; product identity and evidence are often conflated with full-length thymosin beta-4.

PEPTIDE CARDTB-500

Reviewed
August 7, 2026

Human evidence

1/5 · Very limited

U.S. FDANot FDA approved

2026 WADAProhibited

Inspect 2 sources

On this page

WHAT THE EVIDENCE SAYS

TB-500 evidence summary.

The first question for TB-500 is entity identity: evidence about full-length thymosin beta-4 should not be treated as direct evidence for every TB-500 product.

Entity type
Peptide fragmentSource snapshot
August 7, 2026Record status
Sources attached

Do not overread this record

Name similarity is not evidence equivalence.

01 / CLASSIFICATION

What is TB-500?

Entity typePeptide fragment

Research categoryRecovery

Known namesTB-500

Editorial unitOne molecule or defined product record

Names, fragments, salts, formulations, routes, and branded products are kept distinct whenever transferring evidence would change the conclusion.

Class: Thymosin-related peptides Class: Repair and extracellular-matrix peptides Goal: Recovery & Tissue Repair

02 / EVIDENCE

TB-500 human and preclinical evidence.

HUMAN

1/5 · Very limited

Human studies of full-length thymosin beta-4 cannot automatically be transferred to products marketed as TB-500.

PRECLINICAL

3/5 · Related preclinical work

Much of the cited tissue-repair literature concerns thymosin beta-4 rather than a verified TB-500 product.

The five-point bars describe the maturity and depth of the evidence base. They do not score effectiveness, safety, or personal suitability.

03 / STATUS

TB-500 FDA and sport status.

U.S. FDANot FDA approved; product identity and peptide-related impurities are material uncertainties.

2026 WADAProhibited at all times under the 2026 WADA List (S2).

Commercial accessPeptideAgent does not route unapproved research substances to sellers.

Status summaries are educational and time-sensitive. Consult current official labeling and anti-doping resources for a decision.

04 / RESEARCH AREAS

What is TB-500 being studied for?

01Actin biology

02Tissue repair

03Cell migration

04Angiogenesis

05 / COMPARISONS

Compare TB-500.

BPC-157 vs TB-500A source-backed comparison of two unapproved recovery-market peptides.TB-500 vs Thymosin Beta-4A marketed fragment name compared with the full-length endogenous peptide it is often confused with.TB-500 vs GHK-CuTwo recovery-market peptides compared by entity identity, route, and human evidence.

06 / LATEST & DEFINING SOURCES

TB-500 primary and official sources.

WADA / 20262026 Prohibited List

World Anti-Doping Agency

Review / 2015Thymosin beta-4 and tissue repair

PubMed

07 / QUESTIONS

Questions about TB-500.

Start with identity, research, human evidence, approval, sport status, and the limits of the current record.

EvidenceWhat is the evidence for TB-500?

The first question for TB-500 is entity identity: evidence about full-length thymosin beta-4 should not be treated as direct evidence for every TB-500 product.

ResearchWhat is TB-500 being studied for?

Current source-backed research areas include Actin biology, Tissue repair, Cell migration, Angiogenesis. These areas describe investigation, not established personal benefit.

FDA statusIs TB-500 FDA approved?

Current U.S. status for TB-500: Not FDA approved; product identity and peptide-related impurities are material uncertainties.

Sport statusIs TB-500 prohibited in sport?

Current sport-status snapshot for TB-500: Prohibited at all times under the 2026 WADA List (S2).

Evidence limitsWhat are the main evidence limits for TB-500?

Name similarity is not evidence equivalence.

Decision questionWhat is the evidence for BPC-157 and TB-500?

Both are promoted for recovery far beyond the human evidence. The main differences are the shape of the preclinical literature and the identity problem around TB-500.